The efficacy and safety of concurrent chemoradiotherapy for maxillary sinus squamous cell carcinoma patients

Auris Nasus Larynx. 2009 Oct;36(5):547-54. doi: 10.1016/j.anl.2008.11.002. Epub 2008 Dec 18.

Abstract

Objective: Combined treatment modality, e.g., definitive surgery followed by radiotherapy (RT) and definitive RT with concurrent chemotherapy, has been applied for advanced maxillary sinus squamous cell carcinoma (MSSCC) patients to obtain a better survival with organ preservation in Japan.

Methods: The outcome of 40 patients with MSSCC between 1991 and 2007 in our institute was analyzed retrospectively. There were 36 males and 4 females, the average age being 59.5 years (ranging from 34 to 81 years). The median follow-up time was 66.1 months. All the patients had received a combined treatment consisting of definitive surgery, RT, and intra-arterial or systemic chemotherapy. The chemotherapeutic regimen was different depending on the performance status and/or complications of the patients. Since 1998, concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin regimen (CCRT-PFML) instead of neo-adjuvant chemotherapy has been applied.

Results: The overall 5-year survival rate was 59.2%, the 5-year disease-specific survival rate was 71.7%, and the 5-year organ preservation survival rate was 42.4%. In the group receiving CCRT-PFML, the overall 5-year survival rate was 60.0%, the 5-year disease-specific survival rate was 76.0%, and the 5-year organ preservation survival rate was 60.3%.

Conclusion: CCRT-PFML for advanced MSSCC patients is feasible to preserve the organs without reducing the survival rate.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / radiotherapy*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy / adverse effects*
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Kaplan-Meier Estimate
  • Leucovorin / administration & dosage
  • Male
  • Maxillary Sinus*
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoadjuvant Therapy
  • Organ Preservation / methods
  • Paranasal Sinus Neoplasms / drug therapy*
  • Paranasal Sinus Neoplasms / radiotherapy*
  • Retrospective Studies
  • Tegafur / administration & dosage
  • Treatment Outcome
  • Uracil / administration & dosage

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Tegafur
  • Uracil
  • Carboplatin
  • Cisplatin
  • Leucovorin
  • Fluorouracil
  • Methotrexate